Education
Education sessions
ASH Education Program articles and ASCO Educational Book articles whose titles or stated scope concern MRD, measurable or minimal residual disease, or ctDNA. More session webcasts from ESMO, ASCO, and AACR will be added as they are verified.
Learn: how MRD tests differ covers liquid-biopsy CGP versus an MRD test, the technologies, a short animation, and a comparison chart.
31 articles
- FreeASH Education Program 2021ALL
MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?
Gökbuget N · PMID 35158373
- FreeASH Education Program 2021myeloma
Minimal residual disease in multiple myeloma: why, when, where
Yee AJ, Raje N · PMID 34889430
- FreeASH Education Program 2021lymphoma (indolent NHL)
Does MRD have a role in the management of iNHL?
Del Giudice I, Starza ID, Foà R · PMID 34889425
- FreeASH Education Program 2022AML
Achieving MRD negativity in AML: how important is this and how do we get there?
Hourigan CS · PMID 36485093
- FreeASH Education Program 2022AML
Transplant in AML with measurable residual disease: proceed or defer?
Craddock C · PMID 36485147
- FreeASH Education Program 2023CLL
MRD-directed therapy in CLL: ready for prime time?
Rhodes JM, Lopez CA, Barrientos JC · PMID 38066928
- FreeASH Education Program 2023AML
Understanding differential technologies for detection of MRD and how to incorporate into clinical practice
Cloos J, Ngai LL, Heuser M · PMID 38066915
- FreeASH Education Program 2023ALL
Preventing relapse after CD19 CAR T-cell therapy for pediatric ALL: the role of transplant and enhanced CAR T cells
Talleur AC, Naik S, Gottschalk S · PMID 38066941
- FreeASH Education Program 2024AML
Mutations and MRD: clinical implications of clonal ontogeny
Radich J · PMID 39644022
- FreeASH Education Program 2024AML
Mutation- and MRD-informed treatments for transplant-ineligible patients
Lachowiez CA, DiNardo CD · PMID 39644009
- FreeASH Education Program 2024AML
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient
Heuser M, Shahswar R · PMID 39644001
- FreeASH Education Program 2024ALL
Ph+ ALL: new approaches for upfront therapy
Luskin MR · PMID 39644078
- FreeASH Education Program 2024ALL
Ph- ALL: immunotherapy in upfront treatment
Stelljes M · PMID 39644077
- FreeASH Education Program 2025hematologic malignancies (transplant)
Peri-transplant conundrums: optimizing maintenance therapy using MRD-directed approaches
Raychaudhuri S, Cassaday RD, Percival MM · PMID 41348047
- FreeASH Education Program 2025CLL
The role of MRD monitoring and options for CLL management in relapsed/refractory disease
Sworder B, Siddiqi T · PMID 41348036
- FreeASH Education Program 2025myeloma
Can I stop my treatment, doctor? Is MRD-guided therapy ready for prime time?
Derman BA · PMID 41348032
- FreeASH Education Program 2025lymphoma (DLBCL)
Could treatment modification based on early response assessment improve results in DLBCL?
Raman HS, Crombie JL · PMID 41348022
- FreeASH Education Program 2025hematologic malignancies (transplant)
Posttransplant cells for the win? DLI and adoptive cell therapy to eradicate MRD
Schonewille P, van Rhenen A, Ham RMT, de Witte M · PMID 41347975
- FreeASCO Educational Book 2022gastrointestinal cancers
Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers
Alese OB, Cook N, Ortega-Franco A, Ulanja MB, Tan L, Tie J · PMID 35471832
free (ASCO Educational Book is a public ASCO journal; ascopubs.org may require a browser session; PubMed record verified)
- FreeASCO Educational Book 2023AML/ALL/CML
Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia
Dekker SE, Rea D, Cayuela JM, Arnhardt I, Leonard J, Heuser M · PMID 37311155
free (ASCO Educational Book is a public ASCO journal; ascopubs.org may require a browser session; PubMed record verified)
- FreeASCO Educational Book 2025urothelial carcinoma
Current and Future Role of Circulating DNA in the Diagnosis and Management of Urothelial Carcinoma
Bellmunt J, Russell BM, Szabados B, Valderrama BP, Nadal R · PMID 39883890
free (ASCO Educational Book is a public ASCO journal; ascopubs.org may require a browser session; PubMed record verified)
- FreeASCO Educational Book 2025solid tumors (ctDNA/MRD)
Liquid Biopsy Approaches for Cancer Characterization, Residual Disease Detection, and Therapy Monitoring
Aredo JV, Jamali A, Zhu J, Heater N, Wakelee HA, Vaklavas C, Anagnostou V, Lu J · PMID 40305739
free (ASCO Educational Book is a public ASCO journal; ascopubs.org may require a browser session; PubMed record verified)
- FreeASCO Educational Book 2025ALL
Navigating B-ALL in the Era of Blinatumomab
Zupanec S, Beauchemin M, Rau RE · PMID 40435433
free (ASCO Educational Book is a public ASCO journal; ascopubs.org may require a browser session; PubMed record verified)
- FreeASCO Educational Book 2026pediatric ALL/AML
Measurable Residual Disease in Pediatric Acute Leukemia: Application and Interpretation of Current and Emerging Methodologies
Eidenschink Brodersen L, Kovach AE, Zuna J · PMID 42208016
free (ASCO Educational Book is a public ASCO journal; ascopubs.org may require a browser session; PubMed record verified)
- FreeASCO Educational Book 2026melanoma
Beyond Routine Surveillance Imaging for Melanoma: Emerging Technologies for Detecting Early Recurrence and Guiding Clinical Management
de Souza Carvalho G, Cunha de Sousa Martins CL, Wang K, Farwell MD, Salama AKS · PMID 42066238
free (ASCO Educational Book is a public ASCO journal; ascopubs.org may require a browser session; PubMed record verified)
- FreeASCO Educational Book 2022myeloma
Moving Toward a Cure for Myeloma
Mateos MV, Nooka AK, Larson SM · PMID 35623025
free (ASCO Educational Book is a public ASCO journal; ascopubs.org may require a browser session; PubMed record verified)
- FreeASCO Educational Book 2024myeloma
Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies
Rees MJ, D'Agostino M, Leypoldt LB, Kumar S, Weisel KC, Gay F · PMID 38772002
free (ASCO Educational Book is a public ASCO journal; ascopubs.org may require a browser session; PubMed record verified)
- FreeASCO Educational Book 2022ALL
Innovative Approaches to the Management of Acute Lymphoblastic Leukemia Across the Age Spectrum
Curran E, Muffly L, Luskin MR · PMID 35503981
free (ASCO Educational Book is a public ASCO journal; ascopubs.org may require a browser session; PubMed record verified)
- FreeASCO Educational Book 2026ALL
Evolving Paradigms in the Treatment of Philadelphia Chromosome-Positive ALL
Short NJ, Ribera JM, Abou Dalle I, Goulart H, Ribera J, Mohty M, Torrent A, Bazarbachi A · PMID 42102341
free (ASCO Educational Book is a public ASCO journal; ascopubs.org may require a browser session; PubMed record verified)
- FreeASCO Educational Book 2020HPV-associated oropharyngeal cancer
Novel Strategies to Effectively De-escalate Curative-Intent Therapy for Patients With HPV-Associated Oropharyngeal Cancer: Current and Future Directions
Price KAR, Agrawal N, Chera BS (coauthor) · PMID 32213088
public Educational Book article
- FreeUroToday video interview, Advanced Kidney Cancer 2026oligometastatic clear-cell renal cell carcinoma
K-COMPASS Study Investigates ctDNA and KIM-1 in Oligometastatic Kidney Cancer — Chad Tang
Chad Tang
Review articles
Selected reviews and consensus papers from high-impact journals.
General
Ann Oncol · 2022 · Pascual J et al.
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.
ESMO Precision Medicine Working Group recommendations on the analytical and clinical validity of circulating tumour DNA assays, including uses in advanced cancer and residual-disease assessment.
J Clin Oncol · 2018 · Merker JD et al.
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
ASCO and College of American Pathologists joint review of circulating tumor DNA assays; it found clinical validity and utility in some advanced cancers and, at the time, insufficient evidence for residual-disease detection, treatment monitoring, early-stage cancer, or screening.
Nat Rev Clin Oncol · 2025 · Pantel K et al.
Minimal residual disease as a target for liquid biopsy in patients with solid tumours.
Review of liquid biopsy methods to detect minimal residual disease after surgery or chemotherapy in solid tumors, and of the evidence still needed for routine use.
Cancer Discov · 2021 · Moding EJ et al.
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease.
Review of circulating tumor DNA as a marker of minimal residual disease after treatment of solid tumors, including assay considerations and emerging uses in adjuvant therapy trials.
PubMed 34785539DOIPMCOpen access
Clin Cancer Res · 2024 · Wyatt AW et al.
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group.
RECIST Working Group evaluation of plasma circulating tumor DNA as an early treatment-response biomarker in metastatic cancers, alongside imaging-based RECIST.
Ann Oncol · 2025 · Valenza C et al.
Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis.
Systematic review and meta-analysis of circulating tumor DNA clearance as a preoperative predictor of pathologic complete response after neoadjuvant immune checkpoint therapy in solid tumors.
Clin Cancer Res · 2019 · Coakley M et al.
Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors.
Review of circulating tumor DNA detection of molecular residual disease and of how that information can be used in adjuvant trial design for solid tumors.
Nat Rev Cancer · 2017 · Wan JCM et al.
Liquid biopsies come of age: towards implementation of circulating tumour DNA.
Landmark review of circulating tumour DNA biology and of its developing uses for prognostication, molecular profiling, and disease monitoring.
N Engl J Med · 2018 · Corcoran RB et al.
Application of Cell-free DNA Analysis to Cancer Treatment.
Review of how cell-free DNA analysis is applied to cancer treatment.
Genitourinary
Eur Urol · 2025 · Barata PC et al.
Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers.
Review of newer radiographic and molecular methods to assess tumor burden and minimal residual disease in prostate, renal, and urothelial cancers.
Nat Rev Urol · 2023 · Rose KM et al.
Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.
Review of circulating and urinary tumour DNA for genomic profiling and disease monitoring in upper-tract, lower-tract, and metastatic urothelial carcinoma.
Nat Rev Urol · 2024 · Zieren RC et al.
Diagnostic liquid biopsy biomarkers in renal cell cancer.
Review of blood- and urine-based liquid biopsy biomarkers for diagnosis of renal cell carcinoma, including efforts to distinguish benign from malignant small renal masses.
Eur Urol · 2021 · Casanova-Salas I et al.
Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer.
Systematic review of blood-based liquid biopsies, including circulating tumor DNA and circulating tumor cells, to inform clinical decision-making in prostate cancer.
PubMed 33422353DOIPMCOpen access
GI
Ann Oncol · 2025 · Martínez-Castedo B et al.
Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy.
Review of circulating tumor DNA methods to detect minimal residual disease in colorectal cancer, comparing tumor-informed and tumor-agnostic strategies.
J Clin Oncol · 2022 · Malla M et al.
Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices.
Review of current and evolving uses of circulating tumor DNA in colorectal cancer, including residual-disease assessment and treatment monitoring.
PubMed 35839443DOIPMCOpen access
Nat Rev Clin Oncol · 2020 · Dasari A et al.
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.
White paper from the NCI Colon and Rectal-Anal Task Forces summarizing circulating tumour DNA uses in colorectal cancer and giving guidance for clinical and trial integration.
PubMed 32632268DOIPMCOpen access
Breast
JAMA Oncol · 2026 · Schlam I et al.
Circulating Tumor DNA in Early Breast Cancer: A Review.
Review of circulating tumor DNA for minimal residual disease detection, treatment-response monitoring, and earlier identification of recurrence in early breast cancer.
Clin Cancer Res · 2023 · Medford AJ et al.
Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception.
Review of molecular residual disease detection in breast cancer and of strategies for therapeutic interception after curative-intent treatment.
Lung
Nat Rev Clin Oncol · 2025 · Normanno N et al.
Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
Review of circulating tumour DNA evidence in early-stage and locally advanced NSCLC, and of remaining barriers to clinical implementation beyond molecular profiling in advanced disease.
J Thorac Oncol · 2021 · Rolfo C et al.
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer.
IASLC 2021 consensus statement on liquid biopsy in advanced NSCLC, updating the 2018 statement with guidance on when to test and how to interpret results.
ESMO Open · 2022 · Heitzer E et al.
Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer.
Recommendations on the practical implementation of circulating tumor DNA mutation testing in metastatic NSCLC.
PubMed 35202954DOIPMCOpen access
Nat Rev Clin Oncol · 2018 · Abbosh C et al.
Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.
Review of challenges to using circulating tumour DNA for earlier cancer detection and for molecular residual disease assessment in early-stage NSCLC.
Head and neck
JAMA Oncol · 2023 · Lang Kuhs KA et al.
Circulating Tumor HPV DNA for Surveillance of HPV-Positive Oropharyngeal Squamous Cell Carcinoma: A Narrative Review.
Narrative review of circulating tumor HPV DNA for surveillance after treatment of HPV-positive oropharyngeal squamous cell carcinoma.
PubMed 37824111DOIPMCOpen access
Lancet Oncol · 2022 · Lee VH et al.
International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic.
International recommendations on measuring plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma in resource-constrained settings.
PubMed 36455583DOIPMCOpen access
Hematologic
Blood · 2026 · Cloos J et al.
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.
2025 consensus update from the ELN-DAVID MRD Working Party on measurable residual disease assessment in acute myeloid leukemia, aligned with the ELN 2022 genetic risk classification.
Blood · 2026 · Kotrova M et al.
International Cross-Age Consensus Guideline on Measurable Residual Disease Assessment in Acute Lymphoblastic Leukemia.
International cross-age consensus guideline on methods, sampling, reporting thresholds, and interpretation of measurable residual disease assessment in acute lymphoblastic leukemia.
Lancet Oncol · 2025 · Sanz J et al.
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee.
Best-practice recommendations from the EBMT Practice Harmonisation and Guidelines Committee on measurable residual disease-guided interventions around allogeneic transplantation in acute myeloid leukemia.
Nat Rev Clin Oncol · 2025 · Paiva B et al.
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma.
Review of opportunities and challenges for measurable residual disease assessment in the clinical management of multiple myeloma, including next-generation flow cytometry and sequencing.
JAMA Oncol · 2025 · Roschewski M et al.
Circulating Tumor DNA as Measurable Residual Disease in Aggressive B-Cell Lymphoma: A Narrative Review.
Narrative review of circulating tumor DNA as a measurable residual disease marker in aggressive B-cell lymphoma, including end-of-therapy assessment and earlier detection of relapse.
Leukemia · 2021 · Wierda WG et al.
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.
Expert review and consensus recommendations on measurable residual disease assessment in chronic lymphocytic leukemia and its association with time-to-event outcomes.
PubMed 34168283DOIPMCOpen access
JAMA Oncol · 2024 · Rios-Olais FA et al.
Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis.
Systematic review and meta-analysis of the association between measurable residual disease status and clinical outcomes, including progression-free survival, in chronic lymphocytic leukemia in the era of targeted agents.
PubMed 38990562DOIPMCOpen access
Slides and webcasts from meetings
Conference abstracts that already have a slide or webcast link. An ASCO or ESMO member login may be required.
- Level 2ESMO Breast Cancer 2026
416O - SMART: On-treatment ctDNA dynamics predicts response and progression in metastatic breast cancer
Pedram Razavi · Abstract 416O · Proffered Paper (oral) · SMART
SlidesWebcastSlides + webcast. An ASCO or ESMO member login may be required.
- Level 3ESMO Congress 2026
Novel error-corrected tumor-informed whole-genome sequencing ctDNA analysis improves postoperative MRD detection in stage II-III colorectal cancer
Maria Honholt Jorgensen · Abstract 4273P · Poster
PosterPoster PDF. An ASCO or ESMO member login may be required.
- Level 3ESMO Congress 2026
Postoperative TAV16 ctDNA detects molecular residual disease and predicts relapse after pancreatic cancer resection
Miguel García Bartolomé · Abstract 3192eP · ePoster
PosterPoster PDF. An ASCO or ESMO member login may be required.
- Level 3ESMO Congress 2026
MUTE-Seq enables efficient single-digit-ppm tumor-informed ctDNA MRD monitoring in colorectal cancer
Junseok W Hur · Abstract 2446P · Poster
PosterPoster PDF. An ASCO or ESMO member login may be required.
- Level 3ESMO Congress 2026
Clinical utility of ultra-sensitive ctDNA MRD monitoring in advanced NSCLC
Srushti Borkar · Abstract 2728eP · ePoster
PosterPoster PDF. An ASCO or ESMO member login may be required.
- Level 2ESMO Gastrointestinal Cancers Congress 2026
ctDNA status and adjuvant chemotherapy after resection of colorectal liver metastases: An overall survival analysis of the GALAXY study
Kozo Kataoka · Abstract 8O · Proffered Paper (oral) · GALAXY
SlidesWebcastSlides + webcast. An ASCO or ESMO member login may be required.
- Level 2mixedESMO Congress 2025
LBA68 CCTG BR.31: Adjuvant durvalumab (D) in resected non-small-cell lung cancer (NSCLC): Final overall survival (OS) and minimal residual disease (MRD) analyses
Goss, G. · Abstract LBA68 · LBA · CCTG BR.31 · 1,415 randomized; MRD available in 1,131 (80%), of whom 116 (10%) were positive; median follow-up 81 months
Invitae Personalized Cancer Monitoring (tumor-informed), tested on plasma at randomization
Adjuvant durvalumab did not improve OS versus placebo in any prespecified analysis group (all-randomized HR 1.02, 95% CI 0.84-1.25; PD-L1 TC >=25% and EGFR/ALK-negative HR 0.98). MRD positivity was strongly prognostic for worse OS in the placebo arm (HR 6.50 to 8.74 across groups). Durvalumab improved OS among MRD-positive, EGFR/ALK-negative patients with PD-L1 TC >=25% (HR 0.30, 95% CI 0.11-0.80; P=0.011; n=29) and PD-L1 TC >=1% (HR 0.49, P=0.024; n=55); treatment-by-MRD interaction P values were all <0.05.
SlidesWebcastSlides + webcast. An ASCO or ESMO member login may be required.
- Trial in progressESMO Congress 2025
HEROES: De-escalation of anti-HER2 therapies in HER2-positive metastatic breast cancer with long-term persistent response and undetectable MRD in ctDNA
Benjamin Verret (with Thibault De La Motte Rouge) · Abstract 620TiP · Poster / trial-in-progress · HEROES
Trial in progress
PosterPoster PDF. An ASCO or ESMO member login may be required.
- Trial in progressESMO Congress 2025
The SURVIVE HERoes study: Targeting molecular relapse in breast cancer; trastuzumab deruxtecan versus standard-of-care treatment in ctDNA-positive HER2-positive/HER2-low early breast cancer
Kerstin Pfister · Abstract 464eTiP · Poster / trial-in-progress · SURVIVE HERoes
Trial in progress
PosterPoster PDF. An ASCO or ESMO member login may be required.
- Level 2ESMO Congress 2025
Safety and performance of a multi-cancer early detection (MCED) test in an intended-use population: Initial results from the registrational PATHFINDER II study
Nima Nabavizadeh · Abstract LBA64 · Proffered Paper / late-breaking oral · PATHFINDER II
SlidesWebcastSlides + webcast. An ASCO or ESMO member login may be required.
- Level 2ESMO Congress 2025
Molecular residual disease (MRD) analysis from the LAURA study of osimertinib in unresectable stage III EGFR-mutated NSCLC
Edurne Arriola Aperribay · Abstract 1817MO · Mini oral · LAURA
SlidesWebcastSlides + webcast. An ASCO or ESMO member login may be required.
- Level 2positiveESMO Congress 2025
3068O Adjuvant nivolumab vs placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274
Galsky, M.D. · Abstract 3068O · oral · CheckMate 274 · 709 randomized (353 nivolumab, 356 placebo); ctDNA evaluable at cycle 1 day 1 in 133 (18.8%), of whom 54 (40.6%) were ctDNA-positive
Natera Signatera (exploratory)
With median follow-up 43.4 months, adjuvant nivolumab improved DFS versus placebo in the ITT population (median 21.9 vs 11.0 months; HR 0.74, 95% CI 0.61-0.90). In the exploratory Signatera analysis, DFS HR was 0.35 (95% CI 0.2-0.7) in patients who were ctDNA-positive at cycle 1 day 1 (median 7.4 vs 2.8 months) and 0.99 (95% CI 0.5-1.9) in those who were ctDNA-negative.
Full paperSlidesWebcastSlides + webcast. An ASCO or ESMO member login may be required.
- Level 1positiveESMO Congress 2025
LBA8 IMvigor011: A phase III trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer
Powles, T.B. · Abstract LBA8 · LBA · IMvigor011 · 761 enrolled in surveillance; 250 ctDNA-positive patients randomized (167 atezolizumab, 83 placebo); 357 persistently ctDNA-negative
not named in the abstract
Among 250 eligible ctDNA-positive patients after cystectomy, adjuvant atezolizumab improved investigator-assessed DFS versus placebo (median 9.9 vs 4.8 months; HR 0.64, 95% CI 0.47-0.87; P=0.0047) and OS (median 32.8 vs 21.1 months; HR 0.59, 95% CI 0.39-0.90; P=0.0131). In 357 patients who remained ctDNA-negative, DFS was 95.4% at the end of 1-year monitoring and 88.4% at 2 years.
Full paperSlidesWebcastSlides + webcast. An ASCO or ESMO member login may be required.
- Level 1mixedESMO Congress 2025
LBA9 ctDNA-guided adjuvant chemotherapy de-escalation in stage III colon cancer: Primary analysis of the ctDNA-negative cohort from the randomized AGITG DYNAMIC-III trial (Intergroup study of AGITG and CCTG)
Tie, J. · Abstract LBA9 · LBA · DYNAMIC-III · 702 ctDNA-negative of 968 evaluable (72.5%); 353 ctDNA-guided, 349 standard; median follow-up 45 months
tumor-informed (testing 5-6 weeks post-surgery; commercial name not stated in the abstract)
Protocol de-escalation occurred in 90.4%. Oxaliplatin-based chemotherapy use fell (34.8% vs 88.6%, P<0.001), as did grade 3+ adverse events of special interest (6.2% vs 10.6%, P=0.037) and treatment-related hospitalization (8.5% vs 13.2%, P=0.048). Non-inferiority of 3-year RFS was not confirmed (85.3% vs 88.1%; difference -2.8%; 97.5% lower CI -8.0%; NI margin 7.5%). A pre-planned subgroup of clinically low-risk T1-3N1 tumors had difference -2.2% (97.5% lower CI -7.2%), within the NI margin.
Full paperSlidesWebcastSlides + webcast. An ASCO or ESMO member login may be required.
- Level 1mixedESMO Congress 2025
723O Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: Final results of the PEGASUS trial
Marsoni, S. · Abstract 723O · oral · PEGASUS · 135 patients (100 liquid-biopsy-negative, 35 positive); median follow-up 33.5 months
Guardant Reveal (v L1.2)
Among patients with two consecutive post-surgical negative tests, 12 relapses occurred, for a 2-year no-evidence-of-disease rate of 88% (90% CI 81-93). The predefined feasibility threshold (fewer than 14 relapses among 134 negative patients to exclude 85% in favor of 92%) was not met, though the point estimate exceeded 85%. In the 35 positive patients, 13 (37%) relapsed; 2-year time-to-relapse was 87.6% vs 61.5% (HR 3.22, P=0.0013).
SlidesWebcastSlides + webcast. An ASCO or ESMO member login may be required.
- Level 2ESMO Congress 2024
IMpower010: ctDNA status and 5-year disease-free survival follow-up in resected NSCLC after adjuvant chemotherapy followed by atezolizumab or best supportive care
Heather Wakelee · Abstract 1211P · Poster · IMpower010
PosterPoster PDF. An ASCO or ESMO member login may be required.
- Level 2ESMO Congress 2024
Association of ctDNA-based MRD detection and MRD clearance with short-term overall survival in resectable colorectal cancer: Updated analysis of CIRCULATE-Japan GALAXY
Jun Nagata · Abstract 553P · Poster · CIRCULATE-Japan GALAXY
PosterPoster PDF. An ASCO or ESMO member login may be required.
- Level 2ESMO Congress 2024
Association between copy number aberration and ctDNA MRD in colorectal cancer: CIRCULATE-Japan GALAXY
Tomoya Harima · Abstract 555P · Poster · CIRCULATE-Japan GALAXY
PosterPoster PDF. An ASCO or ESMO member login may be required.
- Level 2ESMO Congress 2024
Survival benefit of adjuvant chemotherapy based on MRD detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY
Kozo Kataoka · Abstract 558P · Poster · CIRCULATE-Japan GALAXY
PosterPoster PDF. An ASCO or ESMO member login may be required.
- Level 1mixedESMO Congress 2023
LBA28 The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients
Lonardi, S. · Abstract LBA28 · LBA · PEGASUS · 135 patients; median follow-up 20.8 months at this report
Guardant Reveal (v L1.2)
Post-surgery ctDNA was detected in 35/135 (26%). Relapse occurred in 12/35 (34%) ctDNA-positive vs 9/100 (9%) ctDNA-negative patients (HR 4.37, P=0.0003); the 9 negative relapses were the prespecified false-negative count. After 3 months of CAPOX, 11/35 positive patients converted to negative, but 8/11 later relapsed or re-positivized. Of 23 who received FOLFIRI after CAPOX, 11 converted and were relapse-free at analysis.
SlidesWebcastSlides + webcast. An ASCO or ESMO member login may be required.
- Trial in progressESMO Congress 2023
GUIDE.MRD: A consortium guiding multimodal therapies against minimal residual disease by liquid biopsy and ctDNA implementation in clinical practice
Klaus Pantel · Abstract 237TiP · Poster / trial-in-progress · GUIDE.MRD
Trial in progress
PosterPoster PDF. An ASCO or ESMO member login may be required.
- Trial in progressESMO Asia Congress 2022
Minimal residual disease-guided adjuvant tislelizumab after adjuvant chemotherapy in resected stage IIA-IIIB NSCLC: A single-arm phase II study (Seagull)
Feng Li · Abstract 304TiP · Poster / trial-in-progress · Seagull
Trial in progress
PosterPoster PDF. An ASCO or ESMO member login may be required.
- Level 3ESMO Congress 2022
A tumor-informed, hybrid-capture ctDNA assay for MRD detection in colorectal cancer after curative surgery
Sae-Won Han · Abstract 381P · Poster
PosterPoster PDF. An ASCO or ESMO member login may be required.
- Level 2ESMO Congress 2022
Tumour-naïve ctDNA analysis in resected colorectal cancer in the phase III ASCOLT trial
Daphne Day · Abstract 380P · Poster · ASCOLT
PosterPoster PDF. An ASCO or ESMO member login may be required.